Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The IFN-β-Luc expression and level of hepatitis B virus surface Antigen (HBsAg) showed that DDX3 mediated by the 5-HT<sub>7</sub> agonist (AS-19) increased IFN-β expression and inhibited HBV replication.
|
31172579 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo.
|
31201869 |
2019 |
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interferon β promoter stimulator 1 polymorphisms (IPS-1) regulate interferon (IFN) mediated viral clearance in hepatitis B virus (HBV) infection.
|
30930359 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to hepatitis B virus, infection with hepatitis D virus induces a strong IFN-β/λ response in innate immune competent cell lines.
|
29524530 |
2018 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The reduction in HBV DNA levels by TRK-560 treatment was significantly higher than that by PEG-IFN-α2a treatment both <i>in vitro</i> and <i>in vivo</i> (<i>P</i> = 0.004 and <i>P</i> = 0.046, respectively), and intracellular HBV covalently closed circular DNA (cccDNA) reduction by TRK-560 treatment was also significantly higher than that by PEG-IFN-α2a treatment <i>in vivo</i> (<i>P</i> = 0.0495). cDNA microarrays and ELISA for CXCL10 production revealed significant differences between TRK-560 and PEG-IFN-α2a in the induction potency of interferon-stimulated genes.
|
28373196 |
2017 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the tupaia infection model of HBV clearly indicated the suppression of IFN-β at 31 wpi, which might have contributed to the establishment of chronic HBV infection.
|
28551415 |
2017 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exposure of trophoblast to HBV significantly induced the expression of TLR7 (P<0.001), TLR8 (P=0.005), MyD88 (P=0.004), interferon (IFN)-α (P=0.004), IFN-β (P<0.001) and interleukin (IL)-8 (P=0.001).
|
26315138 |
2015 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study included 24 hepatitis B e-antigen (HBeAg)-positive patients with chronic hepatitis B virus (HBV) genotype C infection who were treated with lamivudine alone for 16-32 weeks, then with both IFN-β and lamivudine for 4 weeks, and finally with IFN-β alone for 20 weeks.
|
25884105 |
2015 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, in HBV-carrier mice, 3p-HBx-siRNA more strongly inhibited HBV replication and promoted IFN production than HBx-siRNA in primary HBV(+) hepatocytes and, therefore, significantly decreased serum hepatitis B surface antigen and increased serum IFN-β.
|
21721030 |
2011 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Temporal treatment with interferon-beta prevents hepatocellular carcinoma in hepatitis B virus X gene transgenic mice.
|
18083266 |
2008 |
Hepatitis B
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.
|
15994231 |
2005 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta.
|
8244255 |
1993 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ribavirin, alone and in combination with interferon-beta, decreased hepatitis B virus levels in most patients, and mean serum hepatitis B virus DNA and DNA polymerase levels at the end of treatment were approximately half of baseline levels (p < 0.05).
|
8340055 |
1993 |